Trial Profile
Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak or Mavyret Regimen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; Renal failure
- Focus Therapeutic Use
- 05 Oct 2021 Status changed from active, no longer recruiting to completed.
- 22 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jul 2021.
- 02 Sep 2020 Status changed from recruiting to active, no longer recruiting.